donate now The Fatty Liver Foundation


Some of the more promising drugs in the pipeline of various pharmaceutical companies


The development and potential of the drug efruxifermin (EFX), previously referred to as AKR-001 by Akero Pharmeceuticals, for the treatment of liver diseases, particularly Nonalcoholic Steatohepatitis (NASH), is a significant advancement in the field of hepatology. Efruxifermin, developed by Akero Therapeutics, is engineered to mimic the biological activity of the endogenous hormone FGF21 (Fibroblast Growth Factor 21), which plays a crucial role in regulating metabolism and energy balance. This drug represents a novel therapeutic approach by targeting the underlying metabolic dysfunctions associated with NASH.

Boehringer Ingelheim

In the exploration of the novel drug survodutide, developed by Boehringer Ingelheim in collaboration with Zealand Pharma, a comprehensive analysis of its clinical trials and therapeutic potential offers a promising outlook for the treatment of metabolic diseases, including MASH (Metabolic Associated Steatohepatitis) and obesity. The drug, a glucagon/GLP-1 receptor dual agonist, targets crucial metabolic pathways, showing significant promise in early clinical evaluations.


Galmed Pharmaceuticals, a clinical-stage biopharmaceutical company, has been at the forefront of developing innovative treatments for liver, metabolic, and fibrotic diseases. Their flagship drug, Aramchol (arachidyl amido cholanoic acid), represents a novel approach in the fight against Nonalcoholic Steatohepatitis (NASH) and has recently expanded its potential applications to other liver conditions.


Inventiva's announcement regarding the clinical development of lanifibranor included plans for a new Phase III trial targeting patients with NASH and compensated cirrhosis, underscoring the drug's progression into later stages of clinical testing. This decision was made public on January 4, 2023, highlighting Inventiva's commitment to advancing lanifibranor's development based on promising earlier phase results.

The pivotal Phase III clinical trial, known as NATiV3, aims to evaluate the long-term efficacy and safety of lanifibranor in adults with NASH. The trial's initiation involved the activation of the first clinical sites and the start of patient screening, marking a significant milestone in lanifibranor's journey towards regulatory approval.


The development of aldafermin by NGM Biopharmaceuticals, Inc. (NGM Bio) represents a significant advancement in the therapeutic landscape for Nonalcoholic Steatohepatitis (NASH), showcasing a novel approach to addressing this complex liver disease. Aldafermin, an engineered analog of the fibroblast growth factor 19 (FGF19), targets the core metabolic dysregulation in NASH. By mimicking FGF19, aldafermin aims to improve liver health, reduce liver fat content, and ameliorate fibrosis in patients with NASH.

Viking Therapeutics

Viking Therapeutics has been a key player in the development of novel therapeutics for metabolic and endocrine disorders, with their investigational drug VK2809 standing out as a significant advancement in the treatment of Nonalcoholic Steatohepatitis (NASH). This discussion provides an overview of VK2809, detailing its clinical development, regulatory milestones, and the implications of its success in recent studies.


The development of Pegozafermin by 89Bio represents a significant advancement in the treatment of Nonalcoholic Steatohepatitis (NASH), a liver disease characterized by inflammation and fibrosis due to fat accumulation. This paper delves into the clinical progress, regulatory milestones, and the implications of Pegozafermin's development, supported by recent studies and announcements.